Day
[용어속성] Term
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial
COVID-19로 입원한 환자의 14일째 임상 상태에 대한 하이드록시클로로퀸의 효과: 무작위 임상 시험
Randomized Controlled Trial
[키워드] 28-day mortality
7-category ordinal scale
absolute difference
activities
acute respiratory syndrome
adjusted odds ratio
Adults
adults hospitalized
analyzed
assigned
blinded
clinical
clinical status
conducted
coronavirus
coronavirus disease
COVID-19
Day
death
determine
died
discharged
doses
duration of symptom
Effect
Efficacy
enrolled
extracorporeal membrane oxygenation
greater
groups
hospital
Hospitalized
Hydroxychloroquine
hydroxychloroquine group
IMPROVE
Infection
intensive care
interim analysis
interquartile range
Invasive mechanical ventilation
median
median age
multicenter
multivariable
nasal
Noninvasive ventilation
outcome
Patient
patients
Placebo
placebo group
placebo-controlled randomized trial
positive
Primary outcome
randomization
Randomized
Randomly
receiving
Respiratory illness
respiratory symptom
Sample size
secondary outcome
Secondary outcomes
significantly
status
supplemental oxygen
Support
the placebo group
Treatment
Trial
use of hydroxychloroquine
with COVID-19
[DOI] 10.1001/jama.2020.22240 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1001/jama.2020.22240 PMC 바로가기 [Article Type] Randomized Controlled Trial
Post-exposure prophylaxis with hydroxychloroquine for the prevention of COVID-19, a myth or a reality? The PEP-CQ Study
Research article
[키워드] 95% CI
adverse event
assigned
asymptomatic individual
Contact
Controlled clinical trial
COVID-19
COVID-19 case
COVID-19 patient
Day
Direct
drug
Follow-up
group
HCQ
highest
home quarantine
household contact
Hydroxychloroquine
hygiene
in vitro
incidence of COVID-19
Inconclusive
individuals
International
laboratory-confirmed
NNT
Occurrence
offered
Open-label
over
pandemic
participant
Participants
Post-exposure prophylaxis
Prevent
prevention
prevention of COVID-19
Prophylaxis
randomised clinical trial
required
risk
risk reduction
SARS-CoV-2
SARS-COV-2 infection
Serious Adverse Events
significantly
social distancing
therapy
Travel
virucidal
[DOI] 10.1016/j.ijantimicag.2020.106224 [Article Type] Research article
[DOI] 10.1016/j.ijantimicag.2020.106224 [Article Type] Research article
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial
COVID-19(IVERCOR-COVID19) 환자의 입원을 방지하기 위한 Ivermectin: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Randomized Controlled Trial
[키워드] 1:1
acute infectious disease
addition
adherence
administration
Admission
adverse event
adverse events
age
allergy
analyzed
Anthropometric data
antiviral drug
antiviral drugs
Arm
ARMS
assessment
barrier
basal
blinded
Breastfeeding
breastfeeding women
Cardiology
Care
care providers
carried
cause
Chain Reaction
childbearing age
Chloroquine
cirrhosis
component
components
Concomitant
Concomitant medication
Confirmed
connection
contraceptive method
contraceptives
Control
control group
control groups
coordination
Corriente
COVID-19
COVID-19 patient population
criteria
current
Day
death
demographic
demographic data
Diagnosis
diagnosis of COVID-19
dialysis
discharged
dissemination
dose
double-blind
drug
Efficacy
Efficacy and safety
elapsed
element
EOS
Equal
example
exclusion criteria
Final
final visit
first dose
Follow-up
greater
heart rate
Hospitalization
hospitalizations
Hydroxychloroquine
incidence
include
Inclusion
inclusion criteria
inclusion/exclusion criteria
Informed consent
Intervention
Invasive mechanical ventilation
investigator
investigators
Ivermectin
Ivermectin safety
Laboratory
less
liver
Liver cirrhosis
Liver disease
mal-absorptive syndrome
medical history
medication
menstrual
menstrual cycles
Mortality
negative
Negative PCR
number
objective
outcome
outcome assessor
outcome assessors
over
oxygen
oxygen saturation
parallel group
participant
Participants
Participation
Patient
patients with COVID-19
PCR
PCR swab
Placebo
placebo-controlled study
polymerase chain
polymerase chain reaction
Polymerase chain reaction test
postmenopausal
pregnant
Presence
Prevent
Primary outcome
protocol
Public
public health
randomization
Randomized
Randomized controlled trial
randomly permuted blocks
receive
recommendation
recorded
recruitment
reducing
renal replacement therapy
replacement therapy
reproductive
required
Research
Sample size
SARS-CoV2
secondary
severe liver disease
single-center
standard treatment
standard treatment alone
Study protocol
supplementary material
surgical
Swab
table
Tablet
temperature
the patient
Total
Treatment
Trial
Trial registration
use of hydroxychloroquine
Version
Viral
viral pathology
Vital
vital signs
vital status
web system
website
weight
woman
women
[DOI] 10.1186/s13063-020-04813-1 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1186/s13063-020-04813-1 PMC 바로가기 [Article Type] Randomized Controlled Trial
Persistence of Positive RT-PCR Results for Over 70 Days in Two Travelers with COVID-19
Brief Report
Published on
Journal: Disaster Medicine and Public Health Preparedness [Category] COVID-19, COVID19(2023년), MERS, SARS,
Journal: Disaster Medicine and Public Health Preparedness [Category] COVID-19, COVID19(2023년), MERS, SARS,
[키워드] acute respiratory syndrome
Consequences
coronavirus
COVID-19
Day
healthy
infection control
over
Patient
Patient Isolation
polymerase chain
positive
reported
Result
reverse transcription
RT-PCR
SARS-CoV-2
Viral detection
with COVID-19
[DOI] 10.1017/dmp.2020.450 PMC 바로가기 [Article Type] Brief Report
[DOI] 10.1017/dmp.2020.450 PMC 바로가기 [Article Type] Brief Report
COVID-19: The First 30 Days at a UK Level 1 Trauma Centre and Lessons Learnt
Orthopedics
[키워드] Admission
Admissions
age
approval
Autoimmune disease
average
baseline
biochemical
Biomarker
blood tests
Cancer
Care
cause
change
Chest
chest X-ray
clinical symptom
collected
Comorbidities
complex
Computed tomography
contracting the virus
COVID
COVID-19
CXR
Day
demographics
diabete
died
effective
eight
Escalation
group
Hospital epidemiology
Immunosuppressive medication
IMPROVE
incidence
Increased
Injury
Intensive
Isolation
lesson
Lessons learnt
level 1
lockdown
majority
males
management
mechanism
medication
Mortality
Older
orthopedics and trauma
outcome
Patient
patients
performed
positive
positive patients
problem
radiological
reduced
reducing
remote
required
respiratory symptom
Result
second wave
Sex
significantly
study period
survived
Swab
Swab test
Symptom
tested
the disease
time
trauma
virus
Volume
was increased
[DOI] 10.7759/cureus.11547 PMC 바로가기 [Article Type] Orthopedics
[DOI] 10.7759/cureus.11547 PMC 바로가기 [Article Type] Orthopedics
Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID‐19 pneumonia: A pilot study
Original Article
[키워드] addition
adverse event
Allergic reactions
CD4
CD8
Clinical efficacy
conducted
CORD
coronavirus
coronavirus disease‐2019
COVID‐19
COVID‐19 patients
cytokine
Cytokine storm
Day
enrolled
enrolment
evaluated
feasibility
feasible
Ground glass opacity
inflammatory biomarkers
investigated
Lymphocyte count
Lymphocyte subset
Mortality
mortality rate
NK cells
objective
oxygenation index
Patient
performed
pilot study
Pneumonia
radiological
recorded
Result
Safe
Safety
Standard therapy
STEM
stem cell
subset
T cell
T cells
the disease
Treatment
Trial
umbilical
umbilical cord mesenchymal stem cells
[DOI] 10.1111/cpr.12947 PMC 바로가기 [Article Type] Original Article
[DOI] 10.1111/cpr.12947 PMC 바로가기 [Article Type] Original Article
Acute Limb Ischemia: A Rare Complication of COVID-19
Cardiac/Thoracic/Vascular Surgery
[키워드] 48 hour
Above-knee amputation
acute respiratory syndrome
Admission
Antibiotics
anticoagulation
arteriosclerosis obliterans
C-reactive protein
Care
Chest
Complication
concomitant use
coronavirus
cough
COVID-19
CRS
Cytokine release syndrome
Cytokines
D-dimer
Day
decrease
discharged
effective
elevated
Fever
hospital
hypertension
hypothermia
International
leukocyte
limb
lower limb
male
multivitamins
non-invasive ventilation
normalized
observation
oxygen
Pain
Patient
Peripheral pulse
polymerase chain
popliteal
positive
Prednisone
presenting
Prophylactic
SARS-CoV-2
severity
Shortness of breath
surgery
TCZ
tested
therapy
Thromboembolism
Tocilizumab
Vascular
Venous thrombosis
was done
[DOI] 10.7759/cureus.11488 PMC 바로가기 [Article Type] Cardiac/Thoracic/Vascular Surgery
[DOI] 10.7759/cureus.11488 PMC 바로가기 [Article Type] Cardiac/Thoracic/Vascular Surgery
Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID‐19 patients
Research Article
[키워드] adjusted
adjusted hazard ratio
Admission
age
Analysis
association
Asthma
Characteristics
chronic pulmonary disease
Clinical characteristics
clinical factor
Clinical risk factors
Comorbidity
conducted
confidence interval
coronavirus disease
Coronavirus disease 2019
COVID‐19
COVID‐19 patient
Cox regression model
Day
dead
demographic characteristics
diabete
Diagnosis
disease
elapsed
emerging infection diseases
enrolled
Gender
Hospital admission
hospitalized patient
hospitalized patients
Impact
IMPROVE
increased risk
log
male
management
median
Mortality
nasopharyngeal viral load
obesity
Older age
onset of symptom
Patient
patients
performed
polymerase chain reaction
prospective cohort
risk factor
SARS‐CoV‐2
significantly lower
survival
symptom onset
symptoms onset
Viral load
Virological
[DOI] 10.1002/jmv.26601 PMC 바로가기 [Article Type] Research Article
[DOI] 10.1002/jmv.26601 PMC 바로가기 [Article Type] Research Article
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
중증 코로나19 환자에게 5일 또는 10일 동안 렘데시비르 투여
Clinical Trial
[키워드] 1:1
7-point ordinal scale
Alanine
alanine aminotransferase
animal model
animal models
antiviral activity
assigned
baseline
benefit
breath
breathing ambient air
can not
Clinical improvement
clinical status
common adverse event
conducted
constipation
coronavirus disease
Coronavirus disease 2019
Course
Day
distribution
duration of treatment
Efficacy
elevated
Evidence
evidence of
hospitalized patient
hospitalized patients
in vitro
interquartile range
Intravenous remdesivir
less
magnitude
mechanical ventilation
median
nausea
occurred
once daily
Open-label
Ordinal Scale
oxygen
oxygen saturation
Patient
patients
phase 3 trial
Placebo
Pneumonia
primary end point
radiologic
randomization
Randomized
Randomly
receive
Remdesivir
Respiratory failure
RNA polymerase inhibitor
SARS-COV-2 infection
severe COVID-19
significant difference
significantly
subsequent
Treatment
Trial
worsening respiratory failure
[DOI] 10.1056/NEJMoa2015301 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1056/NEJMoa2015301 PMC 바로가기 [Article Type] Clinical Trial